ClinicalTrials.gg
CompletedNCT03205371Updated Apr 5, 2022Results posted

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

A Phase 3 interventional study of MenACYW conjugate vaccine and MMR in Meningitis, Meningococcal, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 37 sites in 4 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2016, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,183
Allocation
Randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Enrollment
8th of 23
1,183 · median 907
Started
2016
with 6 others
Phase 3
13 of 24
none open now
Registered
20th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 8th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 20th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

This Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study was conducted to assess the immunogenicity and safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when administered alone and in combination with other pediatric vaccines in healthy toddlers in South Korea, Thailand, the Russian Federation, and Mexico.

Primary Objective:

  • To describe the immunogenicity profile of MenACYW Conjugate vaccine administered alone or concomitantly with licensed pediatric vaccine(s) (measles-mumps-rubella vaccine [MMR] + Varicella, diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type-b Conjugate vaccine [DTaP-IPV-HB-Hib], or pneumococcal Conjugate vaccine [PCV13]).

Secondary Objective:

  • To describe the immunogenicity profile of licensed pediatric vaccine(s) (MMR + Varicella, DTaP-IPV-HB-Hib, or PCV13) when administered alone or concomitantly with MenACYW Conjugate vaccine.
Read the detailed description

Healthy, meningococcal-vaccine naïve toddlers aged 12 to 23 months were randomized either to a single dose of MenACYW Conjugate vaccine alone or in combination with other pediatric vaccines in healthy toddlers in South Korea and Thailand (MMR + varicella vaccine), the Russian Federation (PCV13), and Mexico (DTaP-IPV-HB-Hib). Immunogenicity (pre- and 30 days post-vaccination) and safety was assessed.

03

Conditions studied

  • Meningitis, Meningococcal

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections
  • MenACYW Conjugate vaccine
04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For South Korea: Korean males and females aged 12 to 23 months on the day of the first study visit.
  • For Mexico: Males and females aged 12 to 23 months on the day of the first study visit.
  • For the Russian Federation: Males and females aged 12 to 14 months or 16 to 23 months on the day of the first study visit (eligible for enrollment to MenACYW Conjugate vaccine group) or 15 to 23 months on the day of the first study visit (eligible for enrollment to the MenACYW Conjugate vaccine positive(+) PCV13 group or the PCV13 group).
  • For Thailand: Thai males and females aged 12 to 23 months on the day of the first study visit
  • Participants had received all recommended standard of care vaccinations according to their age as per local regulations*.
  • For the Russian Federation only, participants aged 15 to 23 months on the day of the first study visit (eligible for enrollment to MenACYW Conjugate vaccine+PCV13 group or the PCV13 group) must not had received the third PCV13 vaccination corresponding to his or her age as per the country's National Immunization Program (NIP). The 2nd dose of PCV13 must had been administered at least 4 weeks before the 3rd dose of PCV13 was administered in the study.
  • For South Korea, participants must not had received the MMR or Varicella vaccination corresponding to his or her age at inclusion.
  • For Mexico, participants must not had received the DTaP-IPV-HB-Hib vaccination corresponding to his or her age at inclusion.
  • For Thailand, participants must not have received the any dose of MMR or V vaccination.
  • form was signed and dated by the parent(s) or guardian if allowed by local regulations (and by independent witnesses if required by local regulations)†.
  • Participant and parent/guardian were able to attend all scheduled visits and to comply with all trial procedures.
  • *Participants must had received the total number of doses expected for each vaccine recommended for his/her age in the respective NIPs, but inclusion of participants with variations in the vaccine administration timeframes is considered acceptable if the total number of doses for the corresponding vaccines had been completed (e.g., in Mexico, 3 infant doses of the pentavalent vaccine must had been administered but the 4th dose due in the 2nd year of life should not had been administered for participants to be included in the trial). For the Russian Federation only, participants that had not received a seasonal flu vaccination from 6 months of age according to the Russian NIP were still eligible to participate in this study. For Thailand only, participants who had received a vaccine ahead of the schedule can still be included in the study provided the first doses of MMR and Varicella vaccines have not been administered prior to inclusion.
  • †In the Russian Federation, as per local regulations, only the participant's parent(s) are entitled to sign an informed consent form. A child under the responsibility of a guardian were not included in the study.

Exclusion criteria

Exclusion Criteria:

  • Participation in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after the study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine).
  • For participants enrolled at sites in the Russian Federation: previous vaccination with the third dose of PCV13 in participants 15 to 23 months of age (eligible for MenACYW Conjugate vaccine+PCV13 group or the PCV13).
  • For participants enrolled at sites in Mexico: known history of seizures, or uncontrolled neurologic disorder (including epilepsy); or encephalopathy of unknown etiology occurring within 7 days following previous vaccination with pertussis containing vaccine; previous vaccination with DTaP-IPV-HB-Hib or DTaP-containing vaccine at 12 to 23 months of age.
  • For participants enrolled at sites in South Korea and Thailand: known history of seizures, cerebral injury, or encephalopathy; previous vaccination with MMR or Varicella at 12 to 23 months of age.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial, according to the Investigator's judgment (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease).
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.
  • Verbal report of thrombocytopenia, as reported by the parent/guardian, contraindicating intramuscular (IM) vaccination by the Investigator's judgment.
  • Known bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination by the Investigator's judgment.
  • Personal history of Guillain-Barré syndrome (GBS).
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
  • For participants enrolled at sites in South Korea or Mexico and Thailand: Moderate or severe acute illness/infection (according to investigator's judgment) on the day of vaccination or febrile illness (temperature >= 38.0 degree Celsius [°C]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • For participants enrolled at sites in the Russian Federation: Acute disease of any severity on the day of vaccination or febrile illness (axillary temperature >= 37.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event had subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,183 participants (actual)

Study arms

  • Experimental
    South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.

    Biological: MenACYW conjugate vaccine · Biological: MMR · Biological: Varicella

  • Experimental
    South Korea (Group 2): MenACYW Conjugate Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.

    Biological: MenACYW conjugate vaccine

  • Active comparator
    South Korea (Group 3): MMR + Varicella Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.

    Biological: MMR · Biological: Varicella

  • Experimental
    Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.

    Biological: MenACYW conjugate vaccine · Biological: MMR · Biological: Varicella

  • Experimental
    Thailand (Group 11):MenACYW Conjugate Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Thailand (Group 12): MMR + Varicella Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.

    Biological: MMR · Biological: Varicella

  • Experimental
    Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.

    Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV-HB-Hib

  • Experimental
    Mexico (Group 5): MenACYW Conjugate Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.

    Biological: DTaP-IPV-HB-Hib

  • Experimental
    Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.

    Biological: MenACYW conjugate vaccine · Biological: PCV13

  • Experimental
    Russian Federation (Group 8): MenACYW Conjugate Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Russian Federation (Group 9): PCV13 Vaccine

    Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.

    Biological: PCV13

Interventions

  • BiologicalMenACYW conjugate vaccine

    Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular

  • BiologicalMMR

    Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous

  • BiologicalVaricella

    Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous

  • BiologicalDTaP-IPV-HB-Hib

    Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular

  • BiologicalPCV13

    Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

    Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.

    Time frame: Day 0 and Day 30 post-vaccination

  2. Percentage of Participants With Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

    Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

    Time frame: Day 0 and Day 30 post-vaccination

  3. Percentage of Participants With >=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

    Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

    Time frame: Day 0 up to Day 30 post-vaccination

  4. Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

    The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>=1:16 for participants with pre-vaccination titers \<1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers \>=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

    Time frame: Day 30 post-vaccination

Secondary outcomes

  1. Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12

    Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.

    Time frame: Day 0 and Day 30 post-vaccination

  2. Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12

    Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations \>=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: \>=10 Ab units/mL, anti-rubella Ab concentrations \>=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations \>=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.

    Time frame: Day 0 and Day 30 post-vaccination

  3. Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

    Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.

    Time frame: Day 0 and Day 30 post-vaccination

  4. Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

    Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).

    Time frame: Day 0 (for tetanus only) and Day 30 post-vaccination

  5. Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

    Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: \>= 0.01 and 0.1 IU/mL at Day 0 and \>= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: \>= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations \>= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers \>= 1:8, anti-hepatitis B surface antigen Ab concentrations \>= 10 mIU/mL, \>= 100 mIU/mL.

    Time frame: Day 0 (tetanus only) and Day 30 post-vaccination

  6. Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

    Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is \< 4 \* lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is \>=4 \* pre-vaccination concentration and if the pre-vaccination concentration is \>= 4 \* LLOQ, then the post-vaccination concentration is \>= 2 \* pre-vaccination concentration.

    Time frame: Day 0 and Day 30 post-vaccination

  7. Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9

    Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.

    Time frame: Day 0 and Day 30 post-vaccination

  8. Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9

    Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations \>=0.35 mcg/mL or \>=1.0 mcg/mL.

    Time frame: Day 0 and Day 30 post-vaccination

  9. Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12

    Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

    Time frame: Within 7 days post vaccination

  10. Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6

    SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

    Time frame: Within 7 days post vaccination

  11. Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9

    SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

    Time frame: Within 7 days post vaccination

  12. Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)

    SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: \> 39.5 degree Celsius, Vomiting: Grade 3: \>= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: \> 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses \>= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.

    Time frame: Within 7 days post vaccination

07

Results

Posted Jun 9, 2020

Participant flow

Study participants were enrolled in South Korea, Mexico, the Russian Federation, and Thailand from 07 November 2016 to 13 June 2018.

Participant flow — Overall Study
MilestoneSouth Korea(Group1):MenACYW Conjugate +MMR +Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10):MenACYW Conjugate + MMR+ Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 Vaccine
Started1075353864242200100100200100100
Safety analysis set (safas)103525386424220010010020010099
Per-protocol analysis set (ppas)92455085424215579681969692
Completed1035253864242190979520010099
Not completed4100001035001
Withdrew: Withdrawal by subject410000402001
Withdrew: Lost to follow-up000000523000
Withdrew: Protocol violation000000100000
Withdrew: Adverse event000000010000

Outcome measures

PrimaryGeometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
titers (1/dilution)Groups 1and10: MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 2 and 11: MenACYW Conjugate VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineRussian Federation (Group 7): MenACYW Conjugate +PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate Vaccine
Serogroup A: Day 05.20 (4.56 to 5.93)6.10 (5.00 to 7.44)5.35 (4.82 to 5.94)5.49 (4.66 to 6.45)5.99 (5.30 to 6.76)8.54 (6.47 to 11.3)
Serogroup A: Day 3043.9 (37.4 to 51.6)30.0 (23.1 to 39.0)31.4 (25.9 to 38.1)37.8 (28.5 to 50.2)24.6 (20.2 to 30.1)49.0 (36.8 to 65.3)
Serogroup C: Day 02.37 (2.11 to 2.65)2.58 (2.15 to 3.10)2.21 (2.11 to 2.31)2.16 (2.00 to 2.34)2.77 (2.43 to 3.16)3.69 (2.84 to 4.81)
Serogroup C: Day 30876 (725 to 1057)600 (456 to 790)749 (633 to 886)666 (538 to 825)205 (156 to 269)309 (218 to 437)
Serogroup Y: Day 03.14 (2.78 to 3.54)3.12 (2.58 to 3.78)2.63 (2.37 to 2.92)2.94 (2.45 to 3.53)2.90 (2.56 to 3.28)3.49 (2.68 to 4.53)
Serogroup Y: Day 3088.9 (75.1 to 105)60.0 (47.3 to 76.3)79.7 (65.7 to 96.6)90.9 (66.8 to 124)139 (111 to 173)172 (130 to 229)
Serogroup W: Day 02.15 (2.00 to 2.30)2.31 (2.02 to 2.64)2.41 (2.22 to 2.62)2.16 (2.04 to 2.30)2.93 (2.54 to 3.38)3.62 (2.73 to 4.79)
Serogroup W: Day 3046.8 (39.1 to 56.0)35.5 (27.6 to 45.7)40.0 (32.5 to 49.3)50.9 (37.2 to 69.8)57.4 (47.9 to 68.6)57.0 (44.3 to 73.5)
PrimaryPercentage of Participants With Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
percentage of participantsGroups 1and 10:MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 2 and 11: MenACYW Conjugate VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineRussian Federation (Group 7): MenACYW Conjugate +PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate Vaccine
Serogroup A: Day 0 (>=1:4)75.1 (68.1 to 81.3)82.8 (73.2 to 90.0)82.6 (75.7 to 88.2)82.3 (72.1 to 90.0)82.1 (76.1 to 87.2)85.4 (76.7 to 91.8)
Serogroup A: Day 0 (>=1:8)37.9 (30.7 to 45.4)44.8 (34.1 to 55.9)45.8 (37.8 to 54.0)46.8 (35.5 to 58.4)49.0 (41.8 to 56.2)54.2 (43.7 to 64.4)
Serogroup A: Day 30 (>=1:4)98.9 (96.0 to 99.9)95.4 (88.6 to 98.7)98.1 (94.4 to 99.6)97.5 (91.2 to 99.7)94.9 (90.8 to 97.5)97.9 (92.7 to 99.7)
Serogroup A: Day 30 (>=1:8)97.7 (94.3 to 99.4)92.0 (84.1 to 96.7)92.9 (87.7 to 96.4)89.9 (81.0 to 95.5)83.7 (77.7 to 88.6)90.6 (82.9 to 95.6)
Serogroup C: Day 0 (>=1:4)9.6 (5.7 to 14.9)16.1 (9.1 to 25.5)12.3 (7.5 to 18.5)7.6 (2.8 to 15.8)19.9 (14.5 to 26.2)36.5 (26.9 to 46.9)
Serogroup C: Day 0 (>=1:8)4.0 (1.6 to 8.0)6.9 (2.6 to 14.4)1.9 (0.4 to 5.6)1.3 (0.0 to 6.9)8.7 (5.1 to 13.5)17.7 (10.7 to 26.8)
Serogroup C: Day 30 (>=1:4)100.0 (97.9 to 100.0)100.0 (95.8 to 100.0)100.0 (97.6 to 100.0)100.0 (95.4 to 100.0)98.5 (95.6 to 99.7)99.0 (94.3 to 100.0)
Serogroup C: Day 30 (>=1:8)100.0 (97.9 to 100.0)100.0 (95.8 to 100.0)100.0 (97.6 to 100.0)100.0 (95.4 to 100.0)93.9 (89.5 to 96.8)99.0 (94.3 to 100.0)
Serogroup Y: Day 0 (>=1:4)32.2 (25.4 to 39.6)28.7 (19.5 to 39.4)19.4 (13.5 to 26.5)25.3 (16.2 to 36.4)21.9 (16.4 to 28.4)32.3 (23.1 to 42.6)
Serogroup Y: Day 0 (>=1:8)18.6 (13.2 to 25.2)17.2 (10.0 to 26.8)11.0 (6.5 to 17.0)12.7 (6.2 to 22.0)14.3 (9.7 to 20.0)15.6 (9.0 to 24.5)
Serogroup Y: Day 30 (>=1:4)99.4 (96.9 to 100.0)96.6 (90.3 to 99.3)98.7 (95.4 to 99.8)100.0 (95.4 to 100.0)98.5 (95.6 to 99.7)99.0 (94.3 to 100.0)
Serogroup Y: Day 30 (>=1:8)99.4 (96.9 to 100.0)95.4 (88.6 to 98.7)98.7 (95.4 to 99.8)98.7 (93.1 to 100.0)97.4 (94.1 to 99.2)97.9 (92.7 to 99.7)
Serogroup W: Day 0 (>=1:4)5.1 (2.4 to 9.4)11.5 (5.7 to 20.1)14.8 (9.6 to 21.4)8.9 (3.6 to 17.4)16.8 (11.9 to 22.8)26.0 (17.6 to 36.0)
Serogroup W: Day 0 (>=1:8)1.1 (0.1 to 4.0)2.3 (0.3 to 8.1)7.7 (4.1 to 13.1)2.5 (0.3 to 8.8)12.8 (8.4 to 18.3)20.8 (13.2 to 30.3)
Serogroup W: Day 30 (>=1:4)98.9 (96.0 to 99.9)96.6 (90.3 to 99.3)97.4 (93.5 to 99.3)96.2 (89.3 to 99.2)95.9 (92.1 to 98.2)96.9 (91.1 to 99.4)
Serogroup W: Day 30 (>=1:8)96.0 (92.0 to 98.4)92.0 (84.1 to 96.7)90.3 (84.5 to 94.5)92.4 (84.2 to 97.2)94.4 (90.2 to 97.2)95.8 (89.7 to 98.9)
PrimaryPercentage of Participants With >=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

Time frame:
Day 0 up to Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
percentage of participantsGroups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 2 and 11: MenACYW Conjugate VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineRussian Federation (Group 7): MenACYW Conjugate +PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate Vaccine
Serogroup A82.5 (76.1 to 87.8)64.4 (53.4 to 74.4)69.0 (61.1 to 76.2)70.9 (59.6 to 80.6)58.2 (50.9 to 65.2)72.9 (62.9 to 81.5)
Serogroup C98.3 (95.1 to 99.6)98.9 (93.8 to 100.0)100.0 (97.6 to 100.0)98.7 (93.1 to 100.0)92.3 (87.7 to 95.7)91.7 (84.2 to 96.3)
Serogroup Y95.5 (91.3 to 98.0)89.7 (81.3 to 95.2)96.8 (92.6 to 98.9)94.9 (87.5 to 98.6)94.4 (90.2 to 97.2)93.8 (86.9 to 97.7)
Serogroup W94.9 (90.6 to 97.6)89.7 (81.3 to 95.2)86.5 (80.0 to 91.4)92.4 (84.2 to 97.2)88.8 (83.5 to 92.8)90.6 (82.9 to 95.6)
PrimaryPercentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11

The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>=1:16 for participants with pre-vaccination titers \<1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers \>=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.

Time frame:
Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
percentage of participantsGroups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 2 and 11: MenACYW Conjugate VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineRussian Federation (Group 7): MenACYW Conjugate +PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate Vaccine
Serogroup A78.5 (71.7 to 84.3)63.2 (52.2 to 73.3)67.1 (59.1 to 74.4)69.6 (58.2 to 79.5)56.1 (48.9 to 63.2)71.9 (61.8 to 80.6)
Serogroup C97.7 (94.3 to 99.4)98.9 (93.8 to 100.0)100.0 (97.6 to 100)98.7 (93.1 to 100.0)90.8 (85.9 to 94.5)91.7 (84.2 to 96.3)
Serogroup Y93.2 (88.5 to 96.4)88.5 (79.9 to 94.3)92.3 (86.9 to 95.9)87.3 (78.0 to 93.8)92.9 (88.3 to 96.0)92.7 (85.6 to 97.0)
Serogroup W86.4 (80.5 to 91.1)83.9 (74.5 to 90.9)82.6 (75.7 to 88.2)82.3 (72.1 to 90.0)82.1 (76.1 to 87.2)90.6 (82.9 to 95.6)
SecondaryGeometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12

Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12
titers (1/dilution)Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 3 and 12: MMR + Varicella Vaccine
Measles: Day 040.0 (37.2 to 43.1)45.0 (40.1 to 50.4)
Measles: Day 302156 (1893 to 2455)2840 (2389 to 3378)
Mumps: Day 05.51 (5.20 to 5.84)5.43 (5.05 to 5.83)
Mumps: Day 3085.9 (74.7 to 98.7)97.6 (83.1 to 115)
Rubella: Day 05.94 (5.32 to 6.63)7.12 (6.07 to 8.34)
Rubella: Day 3087.6 (79.4 to 96.7)104 (91.2 to 118)
Varicella: Day 00.556 (0.484 to 0.638)0.665 (0.508 to 0.869)
Varicella: Day 3013.4 (11.6 to 15.4)17.4 (15.2 to 19.9)
SecondaryPercentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12

Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations \>=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: \>=10 Ab units/mL, anti-rubella Ab concentrations \>=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations \>=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12
percentage of participantsGroups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella VaccineGroups 3 and 12: MMR + Varicella Vaccine
Measles: Day 00.6 (0.0 to 3.1)0.0 (0.0 to 3.9)
Measles: Day 3096.6 (92.8 to 98.7)97.8 (92.4 to 99.7)
Mumps: Day 07.4 (4.0 to 12.3)6.5 (2.4 to 13.7)
Mumps: Day 3097.7 (94.3 to 99.4)100.0 (96.1 to 100.0)
Rubella: Day 027.3 (20.8 to 34.5)31.5 (22.2 to 42.0)
Rubella: Day 30100.0 (97.9 to 100)100.0 (96.1 to 100)
Varicella: Day 04.0 (1.6 to 8.0)7.6 (3.1 to 15.1)
Varicella: Day 3093.2 (88.5 to 96.4)98.9 (94.1 to 100.0)
SecondaryGeometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
titers (1/dilution)Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 6): DTaP-IPV-HB-Hib Vaccine
PT: Day 017.9 (15.1 to 21.3)20.4 (15.3 to 27.0)
PT: Day 30144 (130 to 159)169 (144 to 198)
FHA: Day 045.5 (37.0 to 55.9)57.4 (41.4 to 79.5)
FHA: Day 30299 (265 to 337)391 (319 to 480)
SecondaryGeometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).

Time frame:
Day 0 (for tetanus only) and Day 30 post-vaccination
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
titers (1/dilution)Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 6): DTaP-IPV-HB-Hib Vaccine
Diphtheria: Day 305.52 (4.94 to 6.17)6.34 (5.51 to 7.30)
Tetanus: Day 00.238 (0.196 to 0.289)0.234 (0.177 to 0.309)
Tetanus: Day 307.06 (6.01 to 8.29)7.11 (5.79 to 8.74)
Polio 1: Day 304560 (3870 to 5373)4034 (3052 to 5332)
Polio 2: Day 307244 (6208 to 8453)5618 (4578 to 6895)
Polio 3: Day 305977 (4958 to 7205)5100 (3840 to 6772)
Hepatitis B: Day 305171 (4104 to 6515)7308 (5135 to 10401)
PRP: Day 3046.6 (39.6 to 54.9)56.2 (41.5 to 76.1)
SecondaryPercentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: \>= 0.01 and 0.1 IU/mL at Day 0 and \>= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: \>= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations \>= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers \>= 1:8, anti-hepatitis B surface antigen Ab concentrations \>= 10 mIU/mL, \>= 100 mIU/mL.

Time frame:
Day 0 (tetanus only) and Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
percentage of participantsMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 6): DTaP-IPV-HB-Hib Vaccine
Diphtheria: Day 30 (>=0.1 IU/mL)100.0 (97.6 to 100)100.0 (94.7 to 100)
Diphtheria: Day 30 (>=1 IU/mL)98.7 (95.4 to 99.8)100.0 (94.7 to 100)
Tetanus: Day 0 (>=0.01 IU/mL)100.0 (97.6 to 100)100.0 (94.6 to 100)
Tetanus: Day 0 (>=0.1 IU/mL)81.3 (74.2 to 87.1)77.6 (65.8 to 86.9)
Tetanus: Day 30 (>=0.1 IU/mL)100.0 (97.6 to 100)100.0 (94.7 to 100)
Tetanus: Day 30 (>=1 IU/mL)98.1 (94.4 to 99.6)98.5 (92.1 to 100.0)
Polio 1: Day 30 (>=8 [1/dilution])100.0 (97.6 to 100)100.0 (94.7 to 100)
Polio 2: Day 30 (>=8 [1/dilution])100.0 (97.6 to 100)100.0 (94.7 to 100)
Polio 3: Day 30 (>=8 [1/dilution])100.0 (97.6 to 100)100.0 (94.7 to 100)
Hepatitis B: Day 30 (>=10 mIU/mL)100.0 (97.6 to 100)100.0 (94.7 to 100)
Hepatitis B: Day 30 (>=100 mIU/mL)98.7 (95.4 to 99.8)100.0 (94.7 to 100)
PRP: Day 30 (>=0.15 mcg/mL)100.0 (97.6 to 100)100.0 (94.7 to 100)
PRP: Day 30 (>=1.0 mcg/mL)100.0 (97.6 to 100)100.0 (94.7 to 100)
SecondaryPercentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6

Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is \< 4 \* lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is \>=4 \* pre-vaccination concentration and if the pre-vaccination concentration is \>= 4 \* LLOQ, then the post-vaccination concentration is \>= 2 \* pre-vaccination concentration.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
percentage of participantsMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 6): DTaP-IPV-HB-Hib Vaccine
PT: Day 30/Day 091.0 (85.3 to 95.0)92.6 (83.7 to 97.6)
FHA: Day 30/Day 089.0 (83.0 to 93.5)88.2 (78.1 to 94.8)
SecondaryGeometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9

Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Geometric mean · titers (1/dilution)
Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9
titers (1/dilution)Russian Federation (Group 7):MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 9): PCV13 Vaccine
Serotype 1: Day 00.867 (0.741 to 1.01)0.918 (0.713 to 1.18)
Serotype 1: Day 302.33 (1.98 to 2.75)2.14 (1.63 to 2.81)
Serotype 3: Day 00.409 (0.341 to 0.491)0.414 (0.322 to 0.533)
Serotype 3: Day 300.802 (0.664 to 0.967)0.773 (0.608 to 0.983)
Serotype 4: Day 00.604 (0.511 to 0.715)0.653 (0.507 to 0.840)
Serotype 4: Day 301.97 (1.68 to 2.31)1.49 (1.15 to 1.93)
Serotype 5: Day 00.828 (0.719 to 0.953)0.782 (0.610 to 1.00)
Serotype 5: Day 301.99 (1.70 to 2.31)1.73 (1.33 to 2.24)
Serotype 6A: Day 01.61 (1.33 to 1.95)1.48 (1.09 to 2.00)
Serotype 6A: Day 305.96 (4.99 to 7.13)6.13 (4.47 to 8.41)
Serotype 6B: Day 00.895 (0.715 to 1.12)0.691 (0.514 to 0.929)
Serotype 6B: Day 303.66 (2.99 to 4.50)2.57 (1.83 to 3.61)
Serotype 7F: Day 01.32 (1.12 to 1.55)1.39 (1.08 to 1.77)
Serotype 7F: Day 303.05 (2.59 to 3.58)2.67 (2.05 to 3.47)
Serotype 9V: Day 00.841 (0.710 to 0.997)0.863 (0.660 to 1.13)
Serotype 9V: Day 302.34 (1.95 to 2.81)2.52 (1.92 to 3.30)
Serotype 14: Day 03.25 (2.74 to 3.86)3.00 (2.30 to 3.91)
Serotype 14: Day 307.62 (6.56 to 8.83)6.30 (5.00 to 7.93)
Serotype 18C: Day 00.737 (0.620 to 0.876)0.995 (0.766 to 1.29)
Serotype 18C: Day 302.19 (1.87 to 2.58)2.21 (1.73 to 2.83)
Serotype 19A: Day 01.65 (1.36 to 2.01)1.96 (1.46 to 2.64)
Serotype 19A: Day 305.75 (4.85 to 6.80)5.91 (4.54 to 7.69)
Serotype 19F: Day 01.78 (1.43 to 2.21)1.74 (1.28 to 2.35)
Serotype 19F: Day 305.58 (4.57 to 6.81)5.53 (3.98 to 7.69)
Serotype 23F: Day 00.631 (0.519 to 0.768)0.733 (0.537 to 1.00)
Serotype 23F: Day 302.42 (2.04 to 2.86)2.58 (1.98 to 3.37)
SecondaryPercentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9

Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations \>=0.35 mcg/mL or \>=1.0 mcg/mL.

Time frame:
Day 0 and Day 30 post-vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9
percentage of participantsRussian Federation (Group 7):MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 9): PCV13 Vaccine
Serotype 1: Day 0 (>=0.35 mcg/mL)80.8 (74.6 to 86.1)79.3 (69.6 to 87.1)
Serotype 1: Day 0 (>=1.0 mcg/mL)43.0 (35.9 to 50.3)45.7 (35.2 to 56.4)
Serotype 1: Day 30 (>=0.35 mcg/mL)97.4 (94.0 to 99.1)94.6 (87.8 to 98.2)
Serotype 1: Day 30 (>=1.0 mcg/mL)76.4 (69.8 to 82.3)70.7 (60.2 to 79.7)
Serotype 3: Day 0 (>=0.35 mcg/mL)49.2 (42.0 to 56.5)53.3 (42.6 to 63.7)
Serotype 3: Day 0 (>=1.0 mcg/mL)22.3 (16.6 to 28.8)18.5 (11.1 to 27.9)
Serotype 3: Day 30 (>=0.35 mcg/mL)72.3 (65.3 to 78.5)76.1 (66.1 to 84.4)
Serotype 3: Day 30 (>=1.0 mcg/mL)48.2 (40.9 to 55.5)38.0 (28.1 to 48.8)
Serotype 4: Day 0 (>=0.35 mcg/mL)66.8 (59.7 to 73.4)68.5 (58.0 to 77.8)
Serotype 4: Day 0 (>=1.0 mcg/mL)33.7 (27.1 to 40.8)38.0 (28.1 to 48.8)
Serotype 4: Day 30 (>=0.35 mcg/mL)92.7 (88.0 to 95.9)90.2 (82.2 to 95.4)
Serotype 4: Day 30 (>=1.0 mcg/mL)80.1 (73.7 to 85.5)62.0 (51.2 to 71.9)
Serotype 5: Day 0 (>=0.35 mcg/mL)81.3 (75.1 to 86.6)76.1 (66.1 to 84.4)
Serotype 5: Day 0 (>=1.0 mcg/mL)41.5 (34.4 to 48.7)50.0 (39.4 to 60.6)
Serotype 5: Day 30 (>=0.35 mcg/mL)94.8 (90.6 to 97.5)90.2 (82.2 to 95.4)
Serotype 5: Day 30 (>=1.0 mcg/mL)71.2 (64.2 to 77.5)69.6 (59.1 to 78.7)
Serotype 6A: Day 0 (>=0.35 mcg/mL)90.2 (85.1 to 94.0)82.6 (73.3 to 89.7)
Serotype 6A: Day 0 (>=1.0 mcg/mL)63.7 (56.5 to 70.5)65.2 (54.6 to 74.9)
Serotype 6A: Day 30 (>=0.35 mcg/mL)97.4 (94.0 to 99.1)96.7 (90.8 to 99.3)
Serotype 6A: Day 30 (>=1.0 mcg/mL)96.3 (92.6 to 98.5)90.2 (82.2 to 95.4)
Serotype 6B: Day 0 (>=0.35 mcg/mL)72.0 (65.1 to 78.2)68.5 (58.0 to 77.8)
Serotype 6B: Day 0 (>=1.0 mcg/mL)44.6 (37.4 to 51.9)41.3 (31.1 to 52.1)
Serotype 6B: Day 30 (>=0.35 mcg/mL)94.8 (90.6 to 97.5)92.4 (84.9 to 96.9)
Serotype 6B: Day 30 (>=1.0 mcg/mL)86.4 (80.7 to 90.9)75.0 (64.9 to 83.4)
Serotype 7F: Day 0 (>=0.35 mcg/mL)87.0 (81.5 to 91.4)88.0 (79.6 to 93.9)
Serotype 7F: Day 0 (>=1.0 mcg/mL)62.7 (55.5 to 69.5)65.2 (54.6 to 74.9)
Serotype 7F: Day 30 (>=0.35 mcg/mL)98.4 (95.5 to 99.7)94.6 (87.8 to 98.2)
Serotype 7F: Day 30 (>=1.0 mcg/mL)80.1 (73.7 to 85.5)83.7 (74.5 to 90.6)
Serotype 9V: Day 0 (>=0.35 mcg/mL)77.2 (70.6 to 82.9)79.3 (69.6 to 87.1)
Serotype 9V: Day 0 (>=1.0 mcg/mL)42.0 (34.9 to 49.3)43.5 (33.2 to 54.2)
Serotype 9V: Day 30 (>=0.35 mcg/mL)95.3 (91.2 to 97.8)92.4 (84.9 to 96.9)
Serotype 9V: Day 30 (>=1.0 microg/mL)74.3 (67.5 to 80.4)75.0 (64.9 to 83.4)
Serotype 14: Day 0 (>=0.35 mcg/mL)95.8 (92.0 to 98.2)92.4 (84.9 to 96.9)
Serotype 14: Day 0 (>=1.0 mcg/mL)83.3 (77.3 to 88.3)87.0 (78.3 to 93.1)
Serotype 14: Day 30 (>=0.35 mcg/mL)99.0 (96.3 to 99.9)98.9 (94.1 to 100.0)
Serotype 14: Day 30 (>=1.0 mcg/mL)97.4 (94.0 to 99.1)94.6 (87.8 to 98.2)
Serotype 18C: Day 0 (>=0.35 mcg/mL)71.5 (64.6 to 77.8)84.8 (75.8 to 91.4)
Serotype 18C: Day 0 (>=1.0 mcg/mL)40.9 (33.9 to 48.2)48.9 (38.3 to 59.6)
Serotype 18C: Day 30 (>=0.35 mcg/mL)95.3 (91.2 to 97.8)92.4 (84.9 to 96.9)
Serotype 18C: Day 30 (>=1.0 mcg/mL)79.1 (72.6 to 84.6)79.3 (69.6 to 87.1)
Serotype 19A: Day 0 (>=0.35 mcg/mL)87.0 (81.5 to 91.4)87.0 (78.3 to 93.1)
Serotype 19A: Day 0 (>=1.0 mcg/mL)62.7 (55.5 to 69.5)69.6 (59.1 to 78.7)
Serotype 19A: Day 30 (>=0.35 mcg/mL)96.3 (92.6 to 98.5)98.9 (94.1 to 100.0)
Serotype 19A: Day 30 (>=1.0 mcg/mL)92.7 (88.0 to 95.9)90.2 (82.2 to 95.4)
Serotype 19F: Day 0 (>=0.35 mcg/mL)87.0 (81.5 to 91.4)89.1 (80.9 to 94.7)
Serotype 19F: Day 0 (>=1.0 mcg/mL)64.2 (57.0 to 71.0)65.2 (54.6 to 74.9)
Serotype 19F: Day 30 (>=0.35 mcg/mL)96.9 (93.3 to 98.8)97.8 (92.4 to 99.7)
Serotype 19F: Day 30 (>=1.0 mcg/mL)88.0 (82.5 to 92.2)85.9 (77.0 to 92.3)
Serotype 23F: Day 0 (>=0.35 mcg/mL)68.2 (61.1 to 74.7)64.1 (53.5 to 73.9)
Serotype 23F: Day 0 (>=1.0 mcg/mL)34.9 (28.2 to 42.1)44.6 (34.2 to 55.3)
Serotype 23F: Day 30 (>=0.35 mcg/mL)96.3 (92.6 to 98.5)93.5 (86.3 to 97.6)
Serotype 23F: Day 30 (>=1.0 mcg/mL)72.3 (65.3 to 78.5)78.3 (68.4 to 86.2)
SecondaryNumber of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12

Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12
ParticipantsSouth Korea(Group1):MenACYW Conjugate +MMR +Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10):MenACYW Conjugate + MMR +Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR +Varicella Vaccine
MenACYW: Tenderness: Any Grade2815—2917—
MenACYW: Tenderness: Grade 310—01—
MenACYW: Erythema: Any Grade2720—2913—
MenACYW: Erythema: Grade 302—00—
MenACYW: Swelling: Any Grade1814—157—
MenACYW: Swelling: Grade 300—00—
MMR: Tenderness: Any Grade21—1017—18
MMR: Tenderness: Grade 31—00—0
MMR: Erythema: Any Grade13—624—10
MMR: Erythema: Grade 30—00—0
MMR: Swelling: Any Grade7—111—4
MMR: Swelling: Grade 30—00—0
Varicella: Tenderness: Any Grade23—1117—14
Varicella: Tenderness: Grade 30—00—1
Varicella: Erythema: Any Grade19—418—13
Varicella: Erythema: Grade 31—00—0
Varicella: Swelling: Any Grade10—212—5
Varicella: Swelling: Grade 30—00—0
SecondaryNumber of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6

SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6
ParticipantsMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib Vaccine
MenACYW: Tenderness: Any Grade6827—
MenACYW: Tenderness: Grade 361—
MenACYW: Erythema: Any Grade4015—
MenACYW: Erythema: Grade 333—
MenACYW: Swelling: Any Grade238—
MenACYW: Swelling: Grade 322—
DTaP-IPV-HB-Hib: Tenderness: Any Grade80—54
DTaP-IPV-HB-Hib: Tenderness: Grade 36—10
DTaP-IPV-HB-Hib: Erythema: Any Grade56—37
DTaP-IPV-HB-Hib: Erythema: Grade 38—5
DTaP-IPV-HB-Hib: Swelling: Any Grade45—30
DTaP-IPV-HB-Hib: Swelling: Grade 38—4
SecondaryNumber of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9

SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9
ParticipantsRussian Federation (Group 7):MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 Vaccine
MenACYW: Tenderness: Any Grade288—
MenACYW: Tenderness: Grade 340—
MenACYW: Erythema: Any Grade4317—
MenACYW: Erythema: Grade 300—
MenACYW: Swelling: Any Grade87—
MenACYW: Swelling: Grade 300—
PCV13: Tenderness: Any Grade34—9
PCV13: Tenderness: Grade 35—1
PCV13: Erythema: Any Grade48—8
PCV13: Erythema: Grade 30—0
PCV13: Swelling: Any Grade19—2
PCV13: Swelling: Grade 30—0
SecondaryNumber of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)

SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: \> 39.5 degree Celsius, Vomiting: Grade 3: \>= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: \> 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses \>= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)
ParticipantsSouth Korea(Group1):MenACYW Conjugate +MMR +Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10):MenACYW Conjugate + MMR +Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 Vaccine
Fever: Any Grade1795613327161232
Fever: Grade 3121010410000
Vomiting: Any Grade6325451569000
Vomiting: Grade 3000001010000
Abnormal crying: Any Grade2196141712462526842
Abnormal crying: Grade 3000000111200
Drowsiness: Any Grade17898773115172564
Drowsiness: Grade 3000001102100
Appetite Lost: Any Grade291081112551252019127
Appetite Lost: Grade 3100002823100
Irritability: Any Grade31121114111464343326169
Irritability: Grade 3000010413400

Adverse events

Collected over AE data were collected from Day 0 up to Day 30 post-vaccination. SR data were collected within 7 days after vaccination. Serious adverse event (SAE) data were collected throughout the study period (up to Day 30 post-vaccination).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine0/103 (0%)6/103 (5.8%)85/103 (82.5%)
South Korea (Group 2): MenACYW Conjugate Vaccine0/52 (0%)4/52 (7.7%)43/52 (82.7%)
South Korea (Group 3): MMR + Varicella Vaccine0/53 (0%)2/53 (3.8%)37/53 (69.8%)
Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine0/86 (0%)0/86 (0%)58/86 (67.4%)
Thailand (Group 11): MenACYW Conjugate Vaccine0/42 (0%)1/42 (2.4%)37/42 (88.1%)
Thailand (Group 12): MMR + Varicella Vaccine0/42 (0%)0/42 (0%)37/42 (88.1%)
Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine0/200 (0%)0/200 (0%)142/200 (71%)
Mexico (Group 5): MenACYW Conjugate Vaccine0/100 (0%)0/100 (0%)65/100 (65%)
Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine0/100 (0%)1/100 (1%)85/100 (85%)
Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine0/200 (0%)0/200 (0%)75/200 (37.5%)
Russian Federation (Group 8): MenACYW Conjugate Vaccine0/100 (0%)0/100 (0%)30/100 (30%)
Russian Federation (Group 9): PCV13 Vaccine0/99 (0%)0/99 (0%)17/99 (17.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSouth Korea(Group1):MenACYW Conjugate +MMR +Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10):MenACYW Conjugate + MMR +Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group 7):MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 Vaccine
BronchiolitisInfections and infestations0/1032/520/530/860/420/420/2000/1000/1000/2000/1000/99
Croup InfectiousInfections and infestations0/1030/520/530/861/420/420/2000/1000/1000/2000/1000/99
Bronchitis ViralInfections and infestations2/1030/520/530/860/420/420/2000/1000/1000/2000/1000/99
BronchitisInfections and infestations0/1031/520/530/860/420/420/2000/1000/1000/2000/1000/99
GastroenteritisInfections and infestations1/1031/520/530/860/420/420/2000/1000/1000/2000/1000/99
Hand-Foot-And-Mouth DiseaseInfections and infestations1/1031/520/530/860/420/420/2000/1000/1000/2000/1000/99
Otitis Media ViralInfections and infestations0/1030/521/530/860/420/420/2000/1000/1000/2000/1000/99
Pneumonia ViralInfections and infestations0/1030/521/530/860/420/420/2000/1000/1000/2000/1000/99
Febrile ConvulsionNervous system disorders0/1030/520/530/860/420/420/2000/1001/1000/2000/1000/99
AsthmaRespiratory, thoracic and mediastinal disorders0/1030/520/530/860/420/420/2000/1001/1000/2000/1000/99
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSouth Korea(Group1):MenACYW Conjugate +MMR +Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10):MenACYW Conjugate + MMR +Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group 7):MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 Vaccine
Injection Site PainGeneral disorders31/10315/5212/5331/8617/4219/4287/20027/10054/10037/2008/1009/99
Injection Site ErythemaGeneral disorders35/10320/528/5336/8613/4216/4267/20015/10037/10055/20017/1008/99
CryingGeneral disorders21/1039/526/5315/8617/4212/4246/20025/10026/1008/2004/1002/99
IrritabilityPsychiatric disorders31/10312/5211/5314/8611/4214/4264/20034/10033/10026/20016/1009/99
NasopharyngitisInfections and infestations29/10317/5213/535/863/426/4229/20018/10015/1002/2001/1000/99
Injection Site SwellingGeneral disorders25/10314/523/5318/867/425/4252/2008/10030/10021/2007/1002/99
Decreased AppetiteMetabolism and nutrition disorders29/10310/528/5311/8612/425/4251/20025/10020/10019/20012/1007/99
PyrexiaGeneral disorders21/10311/5210/536/863/424/4235/2008/10017/10013/2003/1002/99
SomnolenceNervous system disorders17/1038/529/538/867/427/4231/20015/10017/10025/2006/1004/99
VomitingGastrointestinal disorders7/1033/522/536/864/426/4216/2007/1009/1000/2000/1000/99

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(months)South Korea(Group1):MenACYW Conjugate +MMR+ Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10): MenACYW Conjugate + MMR+Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 VaccineTotal
Mean12.7 ± 1.5812.7 ± 1.5012.3 ± 0.9612.4 ± 0.9012.4 ± 0.8812.8 ± 1.7616.4 ± 2.7316.8 ± 2.8316.8 ± 2.9916.5 ± 2.3616.0 ± 3.1016.3 ± 2.2615.2 ± 2.97
Sex: Female, Male
Sex: Female, Male(Participants)South Korea(Group1):MenACYW Conjugate +MMR+ Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10): MenACYW Conjugate + MMR+Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 VaccineTotal
Female491829472323934648785145550
Male58352439191910754521224955633
Race (NIH/OMB)
Race (NIH/OMB)(Participants)South Korea(Group1):MenACYW Conjugate +MMR+ Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10): MenACYW Conjugate + MMR+Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 VaccineTotal
American Indian or Alaska Native0000000000000
Asian100864242001214179
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American0000000000000
White000000200100991989996792
More than one race0000000000000
Unknown or Not Reported1065353000000000212
Region of Enrollment
Region of Enrollment(Participants)South Korea(Group1):MenACYW Conjugate +MMR+ Varicella VaccineSouth Korea (Group 2): MenACYW Conjugate VaccineSouth Korea (Group 3): MMR + Varicella VaccineThailand (Group 10): MenACYW Conjugate + MMR+Varicella VaccineThailand (Group 11): MenACYW Conjugate VaccineThailand (Group 12): MMR + Varicella VaccineMexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib VaccineMexico (Group 5): MenACYW Conjugate VaccineMexico (Group 6): DTaP-IPV-HB-Hib VaccineRussian Federation (Group7): MenACYW Conjugate + PCV13 VaccineRussian Federation (Group 8): MenACYW Conjugate VaccineRussian Federation (Group 9): PCV13 VaccineTotal
South Korea1075353000000000213
Mexico000000200100100000400
Russia000000000200100100400
Thailand000864242000000170
08

Study locations

37 sites
  • Ansan, 425-707, Korea, Republic of
  • Anyang, 431-070, Korea, Republic of
  • Daegu, 41931, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Gwangju, 61469, Korea, Republic of
  • Ilsan, 10444, Korea, Republic of
  • Incheon, 400-700, Korea, Republic of
  • Jeju City, 63241, Korea, Republic of
  • Seoul, 02053, Korea, Republic of
  • Seoul, 05278, Korea, Republic of
  • Seoul, 100-380, Korea, Republic of
  • Seoul, 130-702, Korea, Republic of
  • Seoul, 132-703, Korea, Republic of
  • Seoul, 139-709, Korea, Republic of
  • Seoul, 158-710, Korea, Republic of
  • Suwon-si, 442-723, Korea, Republic of
  • Wŏnju, 162, Korea, Republic of
  • Yangsan, 626-770, Korea, Republic of
  • Acapulco, 39670, Mexico
  • Mexico City, 04530, Mexico
  • Tlaltizapan, 62770, Mexico
  • Barnaul, 656054, Russian Federation
  • Kazan', 420012, Russian Federation
  • Krasnodar, 350015, Russian Federation
  • Moscow, 119296, Russian Federation
  • Murmansk, 183031, Russian Federation
  • Novosibirsk, 630102, Russian Federation
  • Perm, 614066, Russian Federation
  • Saint Petersburg, 191025, Russian Federation
  • Saint Petersburg, 197022, Russian Federation
  • Saint Petersburg, 197101, Russian Federation
  • Samara, 443079, Russian Federation
  • Smolensk, 214014, Russian Federation
  • Tomsk, 634050, Russian Federation
  • Yekaterinburg, 620028, Russian Federation
  • Pathum Wan, Bangkok 10330, Thailand
  • Rajthevi, Bangkok 10400, Thailand
09

References and documents

Publications

  • Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, Perminova O, Kobashi IAR, Bae CW, Ojeda J, Park J, Chansinghakul D, B'Chir S, Neveu D, Bonaparte M, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect. 2021 Apr 5;149:e90. doi: 10.1017/S0950268821000698. PubMed 33814028 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Jun 2020, 1 year 10 months after primary completion. A results delay was requested in Jul 2019.

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2017
First posted
Jul 2, 2017
StartActual
Nov 7, 2016
Primary completionActual
Jul 19, 2018
CompletionActual
Jul 19, 2018
Results delay requested
Jul 17, 2019
Results first posted
Jun 9, 2020
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03205371
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Nov 7, 2016
Primary completion
Jul 19, 2018
Completion
Jul 19, 2018
Results posted
Jun 9, 2020
Last update
Apr 5, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Measles-Mumps-Rubella Vaccine · 13-valent pneumococcal vaccine

Start the discussion